![]() |
市場調查報告書
商品編碼
2088946
乳房超音波市場:按產品、檢查方法、技術、探頭類型、應用和最終用戶分類-2026-2032年全球市場預測Breast Ultrasound Market by Product, Modality, Technology, Transducer Type, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,乳房超音波市場將成長至 73.3 億美元,複合年成長率為 10.94%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 35.4億美元 |
| 預計年份:2026年 | 39.4億美元 |
| 預測年份 2032 | 73.3億美元 |
| 複合年成長率 (%) | 10.94% |
乳房超音波已從輔助影像工具發展成為現代乳房診療的核心要素。它在診斷檢測中發揮著尤為重要的作用,可輔助影像引導下的切片檢查,並作為緻密型乳房組織女性的輔助篩檢。全球疾病負擔也印證了這項臨床證據。根據世界衛生組織下屬機構國際癌症研究機構(IARC)統計,2022年全球新增乳癌病例約230萬例,死亡病例約67萬例,使乳癌成為全球女性最常見的癌症之一。
乳房超音波領域正經歷著三大協同變革:人們對高密度乳房的認知不斷提高、工作流程現代化以及個人化篩檢的興起。在美國,FDA 全國範圍內的高密度乳房病例通報要求進一步凸顯了輔助影像檢查的重要性。同時,臨床學會也持續認可,在某些高密度乳房族群中,超音波能夠發現乳房X光攝影無法檢測到的癌症,尤其是在將其作為基於風險的影像檢查方案的一部分時。
人工智慧 (AI) 正逐步提升整個乳房超音波工作流程的價值,它能夠輔助病灶檢測、影像品質評估、分割、風險評分和結構化報告產生。這種影響是累積的,因為 AI 並非取代單一步驟,而是提升從影像擷取和解讀到後續優先排序和時間序列比較等各個環節的一致性。在高通量乳房攝影診斷中,此效果特別顯著。
在亞太地區,人工智慧的應用預計將長期保持活躍,這主要得益於中國、印度、日本、韓國和澳洲等國家對乳癌早期診斷意識的提高,以及癌症篩檢系統、醫院基礎設施和女性健康篩檢服務覆蓋範圍的不斷擴大。北美地區仍然是一個高價值地區,這得益於其嚴格的乳癌篩檢通知政策、完善的保險報銷體系、先進的影像中心,以及手持式超音波設備、自動化乳房超音波設備和人工智慧輔助決策系統在乳房攝影影像工作流程中的廣泛臨床應用。
東協市場正透過私人醫院網路、醫療旅遊以及政府對癌症治療的投資而不斷擴張,其中可攜式乳房超音波設備在改善大城市以外地區的醫療服務可及性以及支持早期診斷評估方面發揮著尤為重要的作用。海灣合作理事會(GCC)國家優先發展先進的醫院基礎設施、婦女健康計畫和高階影像服務,因此該地區樂於接受高階超音波設備、自動化乳房超音波設備、彈性成像技術和人工智慧輔助診斷平台。
美國在乳房超音波的應用方面處於主導地位,這得益於其對乳癌的高度重視、完善的乳房緻密病變預警系統、強大的放射科網路以及對輔助篩檢和影像引導切片檢查的需求。加拿大強調各省之間公平的醫療服務獲取途徑和標準化的影像質量,而墨西哥和巴西則透過公共和私人醫療保健投資、都市區影像中心建設以及更廣泛的腫瘤服務發展來提升其診斷能力。
產業領導者應優先考慮經臨床檢驗的乳房超音波解決方案,這些方案能夠提高診斷可靠性、加快工作流程,並方便緻密型乳房、有症狀和高風險患者獲得診療服務。醫療系統需要規範影像方案,增加對超音波技師和放射科醫生的培訓投入,並統一基於BI-RADS的報告標準,以支持一致的資訊共用、可審計性和後續建議。
本執行摘要基於二手研究,參考了權威公共衛生機構和監管機構的資訊來源、臨床指南、同行評審文獻以及乳房攝影影像技術應用的產業分析。主要參考文獻包括世界衛生組織/國際癌症研究機構的癌症負擔數據、美國食品藥物管理局關於乳房增大的通報指南、放射學實踐標準、BI-RADS報告原則以及已發表的關於輔助超音波在乳房增大患者群體中的應用證據。
乳房超音波在乳癌的檢測、診斷、切片檢查指導以及女性影像檢查的可近性方面發揮著日益重要的策略作用。在緻密型乳房疾病高發生率、篩檢意識強、診斷能力與臨床醫生對安全、無輻射、即時影像的需求高度契合的地區,乳房超音波的作用尤其顯著,因為這些影像方式可以作為乳房X光攝影X光攝影、磁振造影和數位乳房斷層合成的補充。
The Breast Ultrasound Market is projected to grow by USD 7.33 billion at a CAGR of 10.94% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 3.54 billion |
| Estimated Year [2026] | USD 3.94 billion |
| Forecast Year [2032] | USD 7.33 billion |
| CAGR (%) | 10.94% |
Breast ultrasound has moved from a supplementary imaging tool to a core component of modern breast care, especially for diagnostic workups, image-guided biopsy support, and supplemental screening in women with dense breast tissue. The clinical rationale is reinforced by global disease burden: the WHO's International Agency for Research on Cancer reported about 2.3 million new breast cancer cases and approximately 670,000 deaths worldwide in 2022, making breast cancer one of the most common cancers among women globally.
For health systems and imaging providers, the breast ultrasound market is shaped by demand for earlier detection, improved lesion characterization, and more accessible diagnostic pathways. Handheld ultrasound, automated breast ultrasound systems, Doppler imaging, and elastography are increasingly evaluated alongside mammography, MRI, and digital breast tomosynthesis to support risk-based, patient-centered breast imaging strategies while reducing unnecessary delays in diagnosis and follow-up care.
The breast ultrasound landscape is being transformed by three converging shifts: dense breast awareness, workflow modernization, and the movement toward personalized screening. In the United States, the FDA's national dense breast notification requirement has raised visibility for supplemental imaging, while clinical societies continue to recognize that ultrasound can detect mammographically occult cancers in selected dense-breast populations, particularly when used as part of a risk-based imaging pathway.
Operationally, providers are adopting automated breast ultrasound, portable systems, cloud-connected reporting, and standardized BI-RADS documentation to reduce variability and expand capacity. These shifts are also increasing expectations for quality assurance, sonographer training, reimbursement clarity, structured reporting, and integration with enterprise imaging platforms, including PACS, RIS, and electronic health records.
Artificial intelligence is beginning to compound value across breast ultrasound workflows by supporting lesion detection, image quality assessment, segmentation, risk scoring, and structured reporting. The impact is cumulative because AI does not replace a single step; it can improve consistency from image acquisition through interpretation, follow-up prioritization, and longitudinal comparison, particularly in high-volume breast imaging settings.
Clinical adoption remains governed by evidence, regulatory clearance, bias testing, cybersecurity, data quality, and radiologist oversight. For providers, the most practical opportunities are AI-enabled triage, automated measurements, reduced inter-reader variability, improved documentation, and workflow efficiency in diagnostic breast imaging programs serving dense-breast, symptomatic, and high-risk patient populations.
Asia-Pacific is positioned for strong long-term adoption as China, India, Japan, South Korea, and Australia expand cancer detection capacity, hospital infrastructure, and women's health screening access amid rising awareness of early breast cancer diagnosis. North America remains a high-value region due to dense breast notification policies, established reimbursement pathways, advanced imaging centers, and broad clinical use of handheld ultrasound, automated breast ultrasound, and AI-enabled decision support in breast imaging workflows.
Europe benefits from organized screening systems, research-intensive healthcare networks, and strict quality standards that support protocol-driven use of ultrasound in diagnostic clarification, image-guided biopsy, and supplemental assessment. Latin America is improving access through public-private diagnostic investments in Brazil, Mexico, and regional urban centers, while the Middle East is building premium diagnostic capacity through tertiary hospitals, women's health initiatives, and national health transformation programs. Africa shows need-driven demand for portable and cost-effective ultrasound where mammography and MRI access remain uneven, making point-of-care imaging and training-led deployment important to improving breast care access.
ASEAN markets are expanding through private hospital networks, medical tourism, and government investment in cancer care, with portable breast ultrasound particularly relevant for improving access outside major cities and supporting earlier diagnostic evaluation. The GCC is emphasizing advanced hospital infrastructure, women's health programs, and premium imaging services, making the region receptive to high-end ultrasound, automated breast ultrasound, elastography, and AI-assisted diagnostic platforms.
The European Union supports breast ultrasound adoption through screening governance, medical device regulation, health technology assessment, and cross-border clinical research, while BRICS economies combine large patient populations with rising diagnostic capacity and increasing investment in oncology infrastructure. G7 countries drive technology standards, reimbursement evidence, regulatory scrutiny, and clinical validation, while NATO-aligned markets often benefit from resilient procurement systems, cybersecurity requirements, interoperable healthcare IT, and established medical technology supply chains that support enterprise-level breast imaging deployment.
The United States is a leading country for breast ultrasound adoption due to high breast cancer awareness, dense breast notification, strong radiology networks, and demand for supplemental screening and image-guided biopsy. Canada emphasizes equitable access across provinces and standardized imaging quality, while Mexico and Brazil are expanding diagnostic capacity through public and private healthcare investments, urban imaging centers, and broader oncology service development.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature screening systems with growing interest in workflow efficiency, structured reporting, and supplemental imaging for dense breasts and diagnostic workups, while Russia maintains demand through large hospital networks and centralized diagnostic infrastructure. China and India represent major volume opportunities driven by population scale, cancer burden, hospital expansion, and increasing awareness of early detection; Japan and South Korea are advanced imaging adopters with strong technology infrastructure and quality-focused clinical practice; Australia benefits from established screening awareness, breast imaging networks, and regional diagnostic services that support ultrasound use in both metropolitan and underserved settings.
Industry leaders should prioritize clinically validated breast ultrasound solutions that improve diagnostic confidence, workflow speed, and access for dense-breast, symptomatic, and high-risk patients. Health systems should standardize acquisition protocols, invest in sonographer and radiologist training, and align reporting with BI-RADS to support consistent communication, auditability, and follow-up recommendations.
Vendors and providers should build evidence around cancer detection, recall rates, biopsy yield, patient experience, workflow efficiency, and total cost of care. Strategic focus should include AI governance, interoperability with PACS/RIS/EHR systems, cybersecurity, reimbursement documentation, quality assurance, and scalable deployment models for both urban breast imaging centers and underserved settings where portable ultrasound can improve timely access to diagnostic evaluation.
This executive summary is based on secondary research from recognized public health agencies, regulatory sources, clinical guidelines, peer-reviewed literature, and industry-level analysis of breast imaging technology adoption. Core references include WHO/IARC cancer burden data, U.S. FDA dense breast notification policy, radiology practice standards, BI-RADS reporting principles, and published evidence on supplemental ultrasound in dense breast populations.
The methodology emphasizes triangulation across disease burden, healthcare infrastructure, reimbursement environment, regulatory context, technology maturity, clinical workflow, and adoption readiness. Insights are synthesized qualitatively to support strategic decision-making without presenting unsupported market-size estimates, market share claims, or unverified growth forecasts.
Breast ultrasound is becoming increasingly strategic in breast cancer detection, diagnostic clarification, biopsy guidance, and accessible women's health imaging. Its role is strongest where dense breast prevalence, screening awareness, and diagnostic capacity converge with clinician demand for safe, radiation-free, real-time imaging that complements mammography, MRI, and digital breast tomosynthesis.
The next phase of the breast ultrasound market will be defined by evidence-based AI, automated acquisition, elastography, standardized reporting, interoperability, and region-specific access models. Organizations that combine clinical quality with scalable workflow integration, regulatory discipline, and patient-centered deployment will be best positioned to improve breast imaging outcomes and strengthen long-term relevance in modern breast care.